Cyclopharm (ASX:CYC) secured a five-year federal supply schedule agreement with the US Veterans Health Administration, expanding Technegas' adoption within the federal healthcare system, according to a Friday filing with the Australian bourse.
Technegas is a radioactive carbon dispersion used in ventilation-perfusion scans to diagnose lung conditions, including pulmonary embolism.
The deal streamlines procurement processes for US federal agencies, including the Veterans Administration (VA), Department of Defense, and Public Health Service hospitals by eliminating individual contracts across VA's 20 regional procurement offices, the filing said.
Shares rose nearly 4% in afternoon trade Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。